Crossmark

TbpB-based oral mucosal vaccine provides heterologous protection against Glässer’s disease caused by different serovars of Spanish field isolates of Glaesserella parasuis

Crossref DOI link: https://doi.org/10.1186/s40813-024-00404-7

Published Online: 2024-11-28

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

González-Fernández, Alba

Mencía-Ares, Oscar

García-Iglesias, María José

Petrocchi-Rilo, Máximo

Miguélez-Pérez, Rubén

Perelló-Jiménez, Alberto

Herencia-Lagunar, Elena

Acebes-Fernández, Vanessa

Gutiérrez-Martín, César B.

Martínez-Martínez, Sonia
Funding

Funding for this research was provided by:

Universidad de León

Junta de Castilla y León
License Information

Text and Data Mining valid from 2024-11-28

Version of Record valid from 2024-11-28
More Information

Article History

Received: 26 April 2024

Accepted: 4 November 2024

First Online: 28 November 2024

Declarations

:

: All procedures involving animals were approved by the institutional bioethical committee (Reference Number OEBA-ULE-003–2022) and performed according to European regulations regarding animal welfare and protection of animals used for experimental and other scientific purposes.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below